Current Neurology and Neuroscience Reports

, Volume 12, Issue 5, pp 592–600

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

Authors

  • Ali Manouchehrinia
    • Division of Clinical NeurologyUniversity of Nottingham
    • Division of Clinical NeurologyUniversity of Nottingham
Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)

DOI: 10.1007/s11910-012-0291-6

Cite this article as:
Manouchehrinia, A. & Constantinescu, C.S. Curr Neurol Neurosci Rep (2012) 12: 592. doi:10.1007/s11910-012-0291-6

Abstract

Multiple sclerosis (MS) is a leading cause of disability among young adults and has a significant economic impact on society. Although MS is not currently a curable disease, costly treatments known as disease-modifying therapies (DMTs) are available to reduce the disease impact in certain types of MS. In the current economic downturn, cost-effectiveness analysis (CEA) of therapies in MS has become an important part of the decision-making process in order to use resources efficiently in the face of the rapidly escalating costs of MS. While some studies have reported costs of DMTs at the level of cost-effectiveness thresholds, some have estimated their costs beyond the tolerance level of health care systems. On the basis of the current literature and given the difficulties in accurately assessing cost-effectiveness in diseases like MS, it is challenging to determine whether DMTs are cost-effective. Further population-based studies are required regarding the cost-effectiveness of therapies in MS.

Keywords

Multiple sclerosisTreatmentDMTCost-effectiveness

Copyright information

© Springer Science+Business Media, LLC 2012